May 28, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Imfinzi combination snags FDA approval for high-risk non-muscle invasive bladder cancer
The FDA has approved an immunotherapy combination therapy for adult patients with Bacillus Calmette-Guérin-naive, high-risk non-muscle invasive bladder cancer.The combination of durvalumab (Imfinzi, AstraZeneca) plus Bacillus Calmette-Guérin (BCG) is the first of its kind to be approved for this patient population, according to a manufacturer-issued press release.
521 words~2 min read
